Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
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
WkR19BFtH3k4XayM
